Andrew Dudum Sells 128,127 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 128,127 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the transaction, the chief executive officer now owns 173,655 shares of the company’s stock, valued at approximately $5,900,796.90. This represents a 42.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, February 18th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29.
• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.22, for a total value of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.08, for a total transaction of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.00, for a total transaction of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $33.85 on Thursday. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The firm’s 50 day simple moving average is $38.88 and its 200-day simple moving average is $28.52. The company has a market cap of $7.52 billion, a P/E ratio of 76.94 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HIMS. Crewe Advisors LLC acquired a new stake in Hims & Hers Health during the 4th quarter worth about $28,000. Raleigh Capital Management Inc. lifted its position in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC grew its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at approximately $38,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on HIMS shares. Citigroup reiterated a “sell” rating and set a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. Leerink Partners lifted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Canaccord Genuity Group upped their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. TD Cowen reaffirmed a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, BTIG Research assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.